Drug Trial Radar · NCT05680129
A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM
Last checked: Nov 19, 2026Latest source record: May 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
623
Actual
Start
Jan 10, 2023
Primary completion
Jul 3, 2024
Study completion Oct 12, 2024
Sponsor
- Lead sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to compare the efficacy and safety of two XW003 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)
Conditions
- T2DM
- Type 2 Diabetes Mellitus
Interventions
Ecnoglutide high dosageDrug
Administered subcutaneously
Ecnoglutide low dosageDrug
Administered subcutaneously
DulaglutideDrug
Administered subcutaneously
MetforminDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in HbA1cTime frame: Baseline, week 32
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ZHONGSHAN Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.